TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged ≥12 years and older inclusive of either sex.~2. Documented clinical history of PAR (for at least 2 years preceding the Screening Visit \[Visit 1\]) and exhibiting a documented positive skin prick test (wheal diameter at least 3 mm greater than negative diluent control wheal) to at least 1 allergen known to induce PAR. Documentation of a positive result within 12 months prior to the Screening Visit (Visit 1) is acceptable.~Exclusion Criteria:~1. Pregnant or lactating women.~2. History of anaphylaxis and/or other severe local reaction(s) to skin testing.~3. History of positive test for HIV, Hepatitis B or Hepatitis C infection.~4. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.~5. Subjects with an active pulmonary disorder or infection.~6. Subjects with posterior subcapsular cataracts or glaucoma

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSP 301 NS (Type: EXPERIMENTAL): None
- GSP 301 Placebo NS pH 3.7 (Type: PLACEBO_COMPARATOR): None
- GSP 301 Placebo NS pH 7.0 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stable, active plaque psoriasis~* Failure to respond to the following systemic therapies: Methotrexate, Cyclosporine, PUVA or Fumarate~Exclusion Criteria:~* Evidence of skin conditions other than psoriasis that would interfere with evaluations of the effect of the study~* Systemic psoriasis therapy within 28 days prior

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence~* Progression after chemotherapy or appropriate TKI treatment for those patients with an EGFR-sensitizing mutation or ALK rearrangement~* KPS ≥ 70, lifespan \> 3 months, PD-L1 TPS of 1% or greater~* Platelet count ≥ 80×10\^9/L，white blood cell count ≥ 3×10\^9/L, neutrophil count ≥ 2×10\^9/L, hemoglobin ≥ 80 g/L~Exclusion Criteria:~* Patients with cardiac pacemaker~* Patients with brain metastasis~* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction, myelosuppression, autoimmune disease, pneumonitis~* Previous treatment with a therapeutic antibody against CTLA4, PD-L1, or PD-1, or PD-L1/PD-1 pathway-targeting agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab and NK immunotherapy (Type: EXPERIMENTAL): In this group, the patients will receive regular Pembrolizumab first to control tumor burden; then NK immunotherapy will be given. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
- Pembrolizumab (Type: ACTIVE_COMPARATOR): In this group, the patients will receive regular Pembrolizumab to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese participant~* Good health or any underlying chronic illness is documented to be in stable condition~* Revaccination Group: received one documented PNEUMOVAX™ 23 vaccination at least 5 years before enrollment in the study~* Primary Vaccination Group: no prior history with PNEUMOVAX™ 23 vaccination Exclusion Criteria:~* Known allergy or sensitivity to any of the components of the study vaccine~* History of pneumococcal conjugate vaccination~* Known or suspected immune dysfunction, immunosuppression, or autoimmune disease. Participants with a history of cancer who are not actively treated and not immunosuppressed will be eligible~* Functional or anatomic asplenia~* Received immunoglobulin within 6 months before study vaccine or is planned during the study~* Received any investigational drugs or vaccines within 2 months before study vaccination~* History of pneumococcal disease (positive culture from blood or other normally sterile site)~* Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection~* History of convulsion~* Previously diagnosed with immunodeficiency or has a close relative with congenital immune deficiency~* Participating in any other clinical trial

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Revaccination Group (Type: EXPERIMENTAL): 0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
- Primary Vaccination Group (Type: EXPERIMENTAL): 0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Patients may be eligible for this study if they:~* Are at least 13 years old (need consent of parent or guardian if under 18).~* Are HIV-positive.~* Are in the 2nd or 3rd trimester (14 to 34 weeks pregnant) and are pregnant with one or two children.~* Have a normal ultrasound exam.~Exclusion Criteria~Patients will not be eligible for this study if they:~* Cannot take ZDV or 3TC.~* Have an active opportunistic (HIV-associated) or bacterial infection, or a severe medical condition.~* Have severe diarrhea.~* Are at risk for premature birth or pregnancy complications.~* Have a family history of phenylketonuria (PKU).~* Plan to breast-feed.~* Abuse alcohol or drugs.~* Cannot visit the same clinic for the duration of the study.~* Have taken certain anti-HIV drugs.

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Lists of Inclusion and Exclusion criteria:~Inclusion Criteria:~* adults or children weighting more than 5 kg~* axillary temperature \>=37.5°C at D0 or history of fever within the previous 24hrs~* confirmed Plasmodium falciparum monoinfection, with parasitemia\>1000mcl~* negative urinary pregnancy test for women of child bearing age before each new administration of treatment~Exclusion Criteria:~* presence of any serious or clinical danger sign of malaria: prostration, consciousness disorders, recent and repeated convulsions, respiratory distress, inability to drink, uncontrollable vomiting, macroscopic haemoglobinuria, jaundice, haemorrhagic shock, systolic BP\< 70 mmHg in adults or \< 50 mmHg in children, spontaneous bleeding, inability to sit or stand~* severe concomitant disease~* allergy to one of the investigational drugs.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Octreotide in Severe Polycystic Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age - 18 years and older~* Diagnosis of Polycystic Liver Disease (PLD) associated with ADPKD or isolated Autosomal Dominant Polycystic liver Disease (ADPLD)~* Severe PLD defined as a liver volume greater than 4000 mL or symptomatic disease due to mass effects from hepatic cysts~* Not a candidate for or declining surgical intervention~Exclusion Criteria:~* Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception~* Creatinine greater than 3mg/dL or hemodialysis dependent~* Cancer or major systemic disease that could prevent completion of the planned follow-up or interfere with data collection or interpretation~* Uncontrolled diabetes mellitus as defined by blood glucose levels of greater than or equal to 250 mg/dL on 2 or more consecutive daily readings despite antidiabetic therapy~* Neurologic/psychologic conditions preventing appropriate informed consent~* Symptomatic gallstones or biliary sludge~* Variceal bleeding or hepatic encephalopathy within prior 30 days~* Uncontrolled hypertension (Systolic blood pressure greater than 160 mmHg; Diastolic blood pressure greater than 100 mmHg)~* Current, or prior use of somatostatin analogue (octreotide, lanreotide) in past 6 months~* History of significant adverse reaction to a somatostatin analogue

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Octreotide (Type: ACTIVE_COMPARATOR): Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
- Placebo (Type: PLACEBO_COMPARATOR): Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria.~* Rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative.~* Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis.~* Inadequate control of symptoms with NSAID.~* Other protocol-defined inclusion criteria do apply.~Exclusion Criteria:~* Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process.~* Subjects taking high potency opioid analgesics.~* Previous exposure to secukinumab or other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor.~* Ongoing use of prohibited psoriasis treatments / medications.~* Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα.~* Previous treatment with any cell-depleting therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 150 mg (Type: EXPERIMENTAL): Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
- Secukinumab 150 mg No load (Type: EXPERIMENTAL): Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients who have been started on Vahelva Respimat in accordance with the approved label in Korea~* Age \>= 18 years at enrolment~* Patients who have signed on the data release consent form~Exclusion criteria:~* Patients with hypersensitivity to Vahelva Respimat or to any of the excipients.~* Patients with a history of hypersensitivity to atropine or its derivatives(e.g. ipratropium, oxitropium, glycopyrronium, clidinium, umeclidinium)~* Patients with asthma~* Current participation in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination) (Type: None): Korean patients with COPD who are newly prescribed with Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apnea Positive Pressure Long-Term Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults age 18 years or older with a diagnosis of OSAS using clinical criteria defined by the study protocol~* Study participation may require seven or more laboratory visits over six months~Exclusion Criteria:~* Prior treatment for OSAS with continuous positive airway pressure or surgery~* Potential sleep apnea complications that may affect the health or safety of the participant, including low blood oxygen, recent near-miss or prior automobile accident due to sleepiness, congestive heart failure, history of angina, coronary artery disease, myocardial infarction or stroke, cardiac rhythm disturbance, and chronic neurological disorders affecting neurocognitive abilities or daily function~* The use of hypnotics, anxiolytics, sedating antidepressants, anticonvulsants, sedating antihistamines, stimulants or other medications likely to affect neurocognitive function and/or alertness~* Respiratory disease requiring medications (unless on stable medications for 2 months)~* Cancer, unless in remission for greater than one year and not taking exclusionary medications~* Self-reported renal failure~* Pregnancy anytime during a subject's participation~* Psychiatric illness, as defined by a DSM-IV diagnosis, except for depression or mild anxiety~* Narcolepsy, idiopathic hypersomnolence, DSM-IV chronic insomnia, restless legs syndrome, or rapid eye movement (REM) behavior disorder~* Current use of diurnal or nocturnal supplemental oxygen~* Significant vision, hearing, or coordination problems~* Difficulty understanding or speaking English~* Currently working night or rotating shifts~* Consumption of more than 10 caffeinated beverages per day (approximately 1,000 mg per day)~* Smokers whose habit interferes with the overnight polysomnogram or with the battery of testing during the day~* Consumption of more than 2 alcoholic beverages per day~* Any illicit drug usage or marijuana usage more than once a week~* Any individual in the household currently on CPAP or on CPAP in the past~* A score of 26 or less on the Mini Mental State Examination (MMSE)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active CPAP (Type: ACTIVE_COMPARATOR): Active Continuous Positive Airway Pressure (CPAP)
- Sham CPAP (Type: PLACEBO_COMPARATOR): Sham Continuous Positive Airway Pressure (CPAP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Computer-Assisted Versus Manual Hair Harvest Comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is male with clinical diagnosis of androgenic alopecia with Norwood-Hamilton grade of IV-VII~* Subject is 30 to 59 years old~* Subject has black or brown hair color~* Subject has straight hair~* Subject agrees to cut hair short (\< 1 mm) on the scalp in the designated study areas for harvesting and implantation~* Subject agrees to have two dot tattoos placed on scalp~* Subject is able to understand and provide written consent; and~* Subject consents to post-operative follow-up per protocol.~Exclusion Criteria:~* Subject has preponderance of grey/white hair~* Subject has blonde hair~* Subject has red hair~* Subject uses hair dye~* Subject has prior history of hair restoration procedure(s) using the strip excision technique~* Subject has prior history of scalp reduction surgery(s)~* Subject has helical hair (curly hair)~* Subject has wavy hair~* Subject has bleeding diathesis~* Subject has active use of anti-coagulation medication~* Subject has used finasteride in the previous 6 months, or plans to use finasteride during the study~* Subject has used minoxidil in the previous 2 weeks, or plans to use minoxidil during the study; or~* Subject has any other condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Computer-Assisted (Type: EXPERIMENTAL): Hair harvest using the computer-assisted system
- Manual Harvest (Type: ACTIVE_COMPARATOR): Hair harvesting via manual technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with suspicion of non-invasive bladder cancer indicated for a transuretheral resection of the bladder~* Above 18 years~* Written informed consent obtained~Exclusion Criteria:~* Gross hematuria. (Note: Gross hematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may interfere with fluorescence cystoscopy. Where the bleed is light, the patient should not be excluded if in the investigator's opinion, rinsing during cystoscopy will alleviate the possible interference with fluorescence cystoscopy).~* Patient with porphyria.~* Known allergy to hexyl aminolevulinate hydrochloride or a similar compound.~* Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days.~* Pregnant or breast-feeding (all women of child-bearing potential must document a negative serum or urine pregnancy test at screening and use the contraceptive pill or intrauterine device (IUD) during the treatments and for at least one month thereafter).~* Conditions associated with a risk of poor protocol compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hexvix cystoscopy group (Type: ACTIVE_COMPARATOR): None
- White light (Type: OTHER): Standard White light cystoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete